Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development

NCT06379971 — Phase 1, Recruiting, 140 participants, University of Colorado, Denver

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Clinical Trial of Maternal Choline Supplements to Mitigate Effects of Prenatal Cannabis Exposure on Early Brain Development

RegistryNCT06379971
StatusRecruiting
PhasePhase 1
Study typeInterventional; randomized, parallel, masking: triple, prevention
Enrollment140 (Estimated)
SponsorUniversity of Colorado, Denver (Other)
ConditionsChild Development, Cannabis Use
InterventionsPlacebo, Choline (Drug)
Datesstart 2024-11-25, primary completion 2029-04-30 (estimated), completion 2029-04-30 (estimated), first posted 2024-04-23, last updated 2025-02-03
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Child Development All trials for Cannabis Use All trials of Placebo All trials of Choline

-Summary

The goal of this study is to determine if providing a nutritional supplement, phosphatidylcholine, to pregnant women who have used cannabis products during the current pregnancy improves the offspring\'s brain-related development during the first 3 months. Participating pregnant women will receive either phosphatidylcholine or a placebo from approximately 16 weeks gestation through birth. The primary outcomes are the child\'s brain responses to sound at 4 weeks corrected age and infant behaviors at 3 months corrected age as reported by the primary caregiver. Secondary outcomes include motor, socio-emotional, language and cognitive development.

Expand all sections  ·  Collapse all

+Detailed description

Phosphatidylcholine (PC) is a form of choline, a nutrient that is sometimes referred to as Vitamin B4 or Vitamin J. Choline is for normal growth everywhere in the body, including in the brain. PC is a naturally occurring substance and can be found in many different kinds of food including milk, liver, and eggs so most people get enough choline. However, when a woman is pregnant and her baby is growing many new cells, more PC may be needed. Research has suggested that the presence of adequate amounts of choline during pregnancy and breastfeeding can help ensure healthy fetal brain development and may have long-lasting positive effects on cognitive function. Problems in behavioral and cognitive development into childhood have been reported in children of mothers who used cannabis during gestation. Alternatively, two studies of maternal choline levels during pregnancy have reported beneficial effects of higher levels on childhood behavioral and cognitive development. This study assesses whether a higher dose of choline taken during pregnancy will have positive results on offspring development.

Participants in this double-blind study will be randomly assigned to receive either placebo or 1028 mg of choline daily throughout pregnancy, until delivery. Vital signs will be taken, potential side effects will be assessed, and study medication will be given at each visit. Blood samples will be taken at enrollment, and approximately at weeks 16, 22, 28, 34. Children will be followed and assessed until 3 months of age.

+Arms and interventions

ArmTypeInterventionsDescription
PlaceboPlacebo comparatorDrug: PlaceboParticipants will take 8 placebo capsules each containing 1100mg Rice Bran Oil and 150mg Pumpkin Seed Oil every day in place of phosphatidylcholine supplement.
PhosphatidylcholineActive comparatorDrug: CholineParticipants will take 8 900mg capsules of phosphatidylcholine every day, the equivalent of approximately 1028 mg of choline per day until delivery
  • Placebo (Drug), also known as rice bran oil and pumpkin seed oil: Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
  • Choline (Drug), also known as Phosphatidylcholine: Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.

+Outcome measures

Primary outcomes

  • Infant Behavior Questionnaire-Revised (IBQ-R) Orienting/Regulation Index [3 months corrected age]: The Orienting/Regulation Index is derived by adding the maternal rating of the infant's duration of attention, distractibility, soothability, cuddling, and smiling on the 91-item IBQ-r
  • Auditory Sensory Gating (P50) [1 month corrected age]: Inhibition of the P50 cerebral auditory evoked response is collected during a paired stimulus auditory sensory gating paradigm

Secondary outcomes

  • Maternal Plasma Choline Levels [approximately 16, 22, 28, 34 weeks gestation]: Plasma choline levels will be used to assess the effects of supplementation throughout gestation
  • Bayley Scales of Infant and Toddler Development [1, 3 and 6 months corrected age]: The Bayley Scales are a standardized assessment of language, cognitive and motor development
  • Child Behavior Checklist (CBCL) 1 1/2-5 [18 months corrected age]: The CBCL assesses a wide range of parent reported behaviors in children on a normative scale for comparison with others, including those assessed in need of clinical interventions for behavioral problems

+Eligibility

Sex: Female, ages: 18 Years to 45 Years, accepts healthy volunteers

Inclusion Criteria:

* Pregnant women who report cannabis use during current pregnancy

Exclusion Criteria:

* Pregnancies complicated by fetal anomaly, including neural tube defect or chromosomal abnormality, or multiple gestations due to increased obstetrical risks
* Women with major preexisting maternal medical morbidities
* Women with a prior history of fetal death
* Current personal history of chronic infections, including HIV
* Current personal or family history out to first-degree relatives of trimethylaminuria or homocystinuria
* Primary language other than English or Spanish
* Evidence of noncompliance

+Locations (1)

FacilityCityCountryStatus
UC HealthAurora, ColoradoUnited StatesRecruiting

+Investigators